Related Experiment Video
Updated: May 21, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[Oral anticoagulants: new horizons]
P Péters1, J O Defraigne, A Gothot
1Service d'Hématologie et d'Immunohématologie, CHU de Liège,Belgique. pierre.peters@chu.ulg.ac.be
Revue Medicale De Liege
|June 14, 2012
Summary
New oral anticoagulants offer improved efficacy and safety over traditional options but carry an increased bleeding risk, especially in vulnerable patients. Further research is needed to define their precise role and monitoring strategies.
Area of Science:
- Pharmacology
- Hematology
- Internal Medicine
Context:
- Traditional anticoagulants like heparins and vitamin K antagonists have long been the standard of care.
- The development of novel synthetic anticoagulants marks a significant advancement in thrombotic disorder management.
Purpose:
- To review the emerging landscape of novel oral anticoagulants (NOACs).
- To compare the efficacy, safety, and pharmacokinetic profiles of NOACs against traditional anticoagulants.
- To highlight the challenges and future directions in anticoagulant therapy.
Summary:
- Novel oral anticoagulants directly target thrombin (Factor IIa) or Factor Xa with reversible action, offering predictable pharmacokinetics and wider therapeutic windows.
- These agents potentially improve patient outcomes and reduce the need for intensive monitoring compared to older therapies.
- Despite promising efficacy, NOACs are associated with an increased risk of hemorrhage, particularly in elderly patients and those with renal insufficiency.
Impact:
- Pharmacological studies suggest NOACs may offer superior efficacy or safety in certain indications.
- The lack of specific laboratory assays and antidotes for NOACs presents a clinical challenge.
- Defining the optimal place for NOACs alongside heparins and vitamin K antagonists is crucial for future anticoagulant strategies.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...